A Meta-Analysis on the Efficacy of Noninvasive Positive Pressure Ventilation Combined With Pressure Support Ventilation in Treating Chronic Heart Failure

ObjectiveTo evaluate the clinical efficacy and safety of noninvasive positive pressure ventilation combined with pressure support ventilation (NPPV-PSV) in the treatment of chronic heart failure (CHF) through a meta-analysis.MethodsA systematic search was conducted using PubMed, Embase, Web of Science, Cochrane Library, CNKI and Wanfang databases to find randomized controlled trials and cohort studies on NPPV-PSV treatment for CHF. The period of search was set from inception until 2024. Eligible studies were included in a systematic review and meta-analysis.ResultsA total of 8 studies with 568 patients were included in this meta-analysis. The meta-analysis revealed that compared with conventional treatment, NPPV-PSV treatment had significant advantages in several aspects: clinical efficacy rate (total effect Z = 5.10, OR = 3.12, 95% confidence interval (CI) [2.01, 4.83], p = 0.000), heart rate (HR) (total effect Z = 16.26, MD = -10.50, 95% CI [-11.76, -9.23], p = 0.000), respiratory rate (RR) (total effect Z = 16.50, MD = -6.44, 95% CI [-7.20, -5.67], p = 0.000) and oxygen saturation (total effect Z = 12.40, MD = 0.09, 95% CI [0.08, 0.11], p = 0.000).ConclusionNoninvasive positive pressure ventilation combined with PSV treatment significantly improves clinical symptoms, reduces HR and RR and increases oxygen saturation in patients with CHF, showing superior effects compared with conventional treatment.